Sagimet Biosciences (SGMT) Other Accumulated Expenses (2022 - 2026)

Sagimet Biosciences' Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $15000.0 for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 6.25% year-over-year to $15000.0 in Q1 2026; TTM through Mar 2026 was $15000.0, a 6.25% decrease from a year earlier, with the FY2025 full-year figure at $27000.0, up 440.0% from the prior year.
• Other Accumulated Expenses fell to $15000.0 in Q1 2026 per SGMT's latest filing, from $27000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $233000.0 in Q4 2023 and bottomed at $1000.0 in Q2 2025.
• The 5-year median for Other Accumulated Expenses is $15500.0 (2025), against an average of $48416.7.
• Across the five-year window, Other Accumulated Expenses sank 97.85% in 2024 and soared 440.0% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $57000.0 in 2022, then surged by 308.77% to $233000.0 in 2023, then sank by 97.85% to $5000.0 in 2024, then surged by 440.0% to $27000.0 in 2025, then plunged by 44.44% to $15000.0 in 2026.
• Per Business Quant, the three latest SGMT Other Accumulated Expenses figures stand at $15000.0 (Q1 2026), $27000.0 (Q4 2025), and $8000.0 (Q3 2025).